stockrowWerewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023.
- Revenue
- +256.1%
- EPS
- +120.0%
- Free cash flow
- +146.5%
Quarter to June 2026, against a year earlier
Follow HOWL
Alert me
Werewolf Therapeutics, Inc. (HOWL) EV/Sales
As of 6 November 2026, Werewolf Therapeutics, Inc. (HOWL) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −4.3× (March 2025) to 10.4× (April 2024); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −2.2× | — |
| FY2023 | 3.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | — |
| Jun 2024 | −0.8× | — |
| Mar 2024 | 9.5× | 197.18% |
| Dec 2023 | 3.2× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PLRX Pliant Therapeutics, Inc. compare | −15.4× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| HOWL Werewolf Therapeutics, Inc. | 2.0× |
| IMA ImageneBio, Inc. compare | 2.7× |
| TIL Instil Bio, Inc. compare | 447× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)